93
GULT inhibitor_Cancer
The Ohio State University
Small molecule
Oncology
Pre-Clinical
The Ohio State University researchers, led by Dr. Ching-Shih Chen, developed and synthesized a novel class of anticancer agents that suppress the ability of cancer cells to utilize glucose, resulting in cellular death in the cancer cells.
These agents take advantage of the differences between glucose uptake rate in non-malignant and malignant cancer cells.
The agents exhibited anticancer activity against androgen-insensitive prostate cancer cells, breast cancer cells, and pancreatic cancer cells.
Currently, this class of glucose transporter inhibitors is in early preclinical evaluations with initial in vivo evaluations of tumor-suppressive activities in human xenograft tumor models beginning.
US 9174951 B2
